Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arcutis Biotherapeutics Inc (NQ: ARQT ) 9.160 +0.060 (+0.66%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,239,054 Open 9.120 Bid (Size) 9.120 (1) Ask (Size) 9.250 (1) Prev. Close 9.100 Today's Range 9.113 - 9.680 52wk Range 1.760 - 13.17 Shares Outstanding 50,241,789 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types September 25, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over September 24, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Performance YTD +167.06% +167.06% 1 Month -13.01% -13.01% 3 Month -2.76% -2.76% 6 Month -7.57% -7.57% 1 Year +64.16% +64.16% More News Read More Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255 September 05, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts August 28, 2024 Via Benzinga Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology September 19, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis August 28, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights July 30, 2024 Via Benzinga Arcutis Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) July 10, 2024 Via Benzinga CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday August 23, 2024 Via Benzinga Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session August 15, 2024 Via Benzinga CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update August 14, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 August 14, 2024 Via InvestorPlace Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update August 14, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc. July 29, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis July 29, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire 7 Biotech Stocks to Keep on Your Clinical Radar July 23, 2024 Via InvestorPlace Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over July 23, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL July 22, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years July 10, 2024 Via Benzinga Exposures Product Safety FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age July 09, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis July 09, 2024 From Arcutis Biotherapeutics, Inc. Via GlobeNewswire Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session July 08, 2024 Via Benzinga The 7 Best Under $10 Stocks to Buy in July 2024 July 06, 2024 Via InvestorPlace Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session June 20, 2024 Via Benzinga Have $5-10? 7 Affordable Stocks That Are About to Breakout. June 13, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
